Stay Alert for Safety Issues With Janus Kinase Inhibitors (Xeljanz, etc)

Questions will pop up about the safety of Janus kinase (JAK) inhibitors...Xeljanz, Olumiant, and the newly approved Rinvoq.

There's an uptick in use of JAK inhibitors for rheumatoid arthritis and other autoimmune diseases...because they're oral.

But these meds may fly under your radar if you're not prescribing them...and they're not on your EHR med list.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote